378 related articles for article (PubMed ID: 30146257)
1. Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway.
He C; Wu T; Hao Y
Biochem Biophys Res Commun; 2018 Sep; 503(4):3093-3099. PubMed ID: 30146257
[TBL] [Abstract][Full Text] [Related]
2. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
[TBL] [Abstract][Full Text] [Related]
3. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873
[TBL] [Abstract][Full Text] [Related]
4. Artemisia capillaris extract AC68 induces apoptosis of hepatocellular carcinoma by blocking the PI3K/AKT pathway.
Yan H; Jung KH; Kim J; Rumman M; Oh MS; Hong SS
Biomed Pharmacother; 2018 Feb; 98():134-141. PubMed ID: 29253760
[TBL] [Abstract][Full Text] [Related]
5. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
[TBL] [Abstract][Full Text] [Related]
6. DMAMCL exerts antitumor effects on hepatocellular carcinoma both in vitro and in vivo.
Yao S; Ye J; Yin M; Yu R
Cancer Lett; 2020 Jul; 483():87-97. PubMed ID: 32268165
[TBL] [Abstract][Full Text] [Related]
7. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
8. Erianin suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK MAPK signaling pathways.
Yang L; Hu Y; Zhou G; Chen Q; Song Z
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32677672
[TBL] [Abstract][Full Text] [Related]
9. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
10. Matrine derivative WM130 inhibits hepatocellular carcinoma by suppressing EGFR/ERK/MMP-2 and PTEN/AKT signaling pathways.
Qian L; Liu Y; Xu Y; Ji W; Wu Q; Liu Y; Gao Q; Su C
Cancer Lett; 2015 Nov; 368(1):126-134. PubMed ID: 26259512
[TBL] [Abstract][Full Text] [Related]
11. Investigation of prunetrin induced G2/M cell cycle arrest and apoptosis via Akt/mTOR/MAPK pathways in hepatocellular carcinoma cells.
Abusaliya A; Bhosale PB; Kim HH; Park MY; Jeong SH; Lee S; Kim GS
Biomed Pharmacother; 2024 May; 174():116483. PubMed ID: 38552440
[TBL] [Abstract][Full Text] [Related]
12. NO donor inhibits proliferation and induces apoptosis by targeting PI3K/AKT/mTOR and MEK/ERK pathways in hepatocellular carcinoma cells.
Liu L; Chen J; Cao M; Wang J; Wang S
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1303-1314. PubMed ID: 31555866
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol inhibited the progression of human hepatocellular carcinoma by inducing autophagy via regulating p53 and the phosphoinositide 3‑kinase/protein kinase B pathway.
Zhang B; Yin X; Sui S
Oncol Rep; 2018 Nov; 40(5):2758-2765. PubMed ID: 30132535
[TBL] [Abstract][Full Text] [Related]
14. LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway.
Song X; Wang J; Zheng T; Song R; Liang Y; Bhatta N; Yin D; Pan S; Liu J; Jiang H; Liu L
Mol Cancer; 2013 Oct; 12(1):114. PubMed ID: 24093956
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation.
Zhai B; Jiang X; He C; Zhao D; Ma L; Xu L; Jiang H; Sun X
Tumour Biol; 2015 Apr; 36(4):2323-34. PubMed ID: 25416439
[TBL] [Abstract][Full Text] [Related]
16. Ethyl pyruvate inhibits proliferation and induces apoptosis of hepatocellular carcinoma via regulation of the HMGB1-RAGE and AKT pathways.
Cheng P; Dai W; Wang F; Lu J; Shen M; Chen K; Li J; Zhang Y; Wang C; Yang J; Zhu R; Zhang H; Zheng Y; Guo CY; Xu L
Biochem Biophys Res Commun; 2014 Jan; 443(4):1162-8. PubMed ID: 24361892
[TBL] [Abstract][Full Text] [Related]
17. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC
Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227
[TBL] [Abstract][Full Text] [Related]
18. Luteolin induces caspase-dependent apoptosis via inhibiting the AKT/osteopontin pathway in human hepatocellular carcinoma SK-Hep-1 cells.
Im E; Yeo C; Lee EO
Life Sci; 2018 Sep; 209():259-266. PubMed ID: 30107166
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of anaplastic lymphoma kinase promotes apoptosis and suppresses proliferation in human hepatocellular carcinoma.
Yu Z; Zhao R
Anticancer Drugs; 2018 Jul; 29(6):513-519. PubMed ID: 29570100
[TBL] [Abstract][Full Text] [Related]
20. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H
Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]